TuftsCSDD-Logo-Color.jpg
Three-Quarters of U.S. Health Plans Reimburse for Off-Label Uses of Prescription Drugs, According to Tufts Center for the Study of Drug Development
10 mars 2009 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - March 10, 2009) - Reflecting recent rapid growth of off-label prescribing of prescription drugs, 75 percent of all health plans in the United States now reimburse patients...
TuftsCSDD-Logo-Color.jpg
Drug Developers Looking to Learn as Much as Possible in Phase I Trials, According to Tufts Center for the Study of Drug Development
27 janv. 2009 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - January 27, 2009) - Under pressure to develop new medicines more quickly and at lower cost, drug sponsors are looking to answer as many questions as possible in Phase I,...
TuftsCSDD-Logo-Color.jpg
The U.S. Remains Preferred Market for Launching New Products, According to Tufts Center for the Study of Drug Development
12 nov. 2008 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - November 12, 2008) - While the number of annual new drug approvals in the United States has declined during the past decade, the U.S. remains the preferred market for...
Adaptive Technologies Expert Illustrates Impact of Data Mining Intelligence at Advanced School of Marketing Research Conference
10 nov. 2008 13h30 HE | Adaptive Technologies, Inc.
PHOENIX, AZ--(Marketwire - November 10, 2008) - Who: Chris Stephens, PhD., Vice President Research & Development at Adaptive Technologies, Inc., (ATi) and Professor, Institute for Nuclear...
Open Innovation Leaders Gather to Share Best Practices at NineSigma's OI Leadership Summit 2008
30 oct. 2008 11h23 HE | NineSigma, Inc.
CLEVELAND, OH--(Marketwire - October 30, 2008) - Earlier this month, open innovation leaders from around the world gathered at NineSigma's Open Innovation Leadership Summit 2008 to share best...
TuftsCSDD-Logo-Color.jpg
Clinical Trial Design Holds Key to Improved Drug Development Efficiency, According to Tufts Center for the Study of Drug Development
30 oct. 2008 10h10 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - October 30, 2008) - Improved protocol design, perhaps more than any other drug development stratagem, holds the key to faster and more efficient development, according to...
TuftsCSDD-Logo-Color.jpg
Fast Track Drugs Reach Market Sooner, According to Tufts Center for the Study of Drug Development
03 sept. 2008 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - September 3, 2008) - New drugs that receive fast track designation by the U.S. Food and Drug Administration (FDA) experience shorter clinical and approval times compared to...
NineSigma Named to Inc. 5000 List of Fastest-Growing Private Companies
26 août 2008 10h23 HE | NineSigma
CLEVELAND, OH--(Marketwire - August 26, 2008) - NineSigma, the leading provider of open innovation solutions for fortune 1000 companies, today announced that it has been named to the annual Inc. 5000...
H2scan Secures $4 Million in Series D Funding
29 juil. 2008 17h49 HE | H2scan
VALENCIA, CA--(Marketwire - July 29, 2008) - H2scan Corporation today announced the Company has secured $4 million in Series D funding from Chrysalix Energy Venture Capital, H5 Capital, L.P.,...
TuftsCSDD-Logo-Color.jpg
Postmarketing Studies Are Becoming the Norm in the U.S., Europe, and Japan, According to Tufts Center for the Study of Drug Development
10 juil. 2008 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - July 10, 2008) - Post-approval study commitments, in which drug developers, as a condition of regulatory approval, agree to conduct research on newly marketed prescription...